Home > Insider Trading > Filing (0001209191-14-012640)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1340652	Chemocentryx Inc.	CCXI	Pharmaceutical Preparations (2834)	943254365

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423084	J. Thomas Schall	C/O Chemocentryx, Inc. 850 Maude Avenue Mountain View CA 94043	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-18	20,000	$0.60	2,168,707	No	4	M	Direct
Common Stock	Disposition	2014-02-18	20,000	$7.05	2,148,707	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-02-18	20,000	$0.00	20,000	$0.60
Common Stock	Stock Option (right to buy)	Acquisiton	2014-02-19	395,000	$0.00	395,000	$7.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
80,000	2004-05-13	2014-05-13	No	4	M	Direct
395,000		2024-02-19	No	4	A	Direct

Footnotes

Includes 20 shares that were inadvertently omitted from the Reporting Person's prior Form 4 filed on July 17, 2013.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Shares sold are associated with stock options which will expire in May 2014.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.00 to $7.14 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
As of February 18, 2014 and prior to this transaction, the option fully vested.
The option was granted on February 19, 2014. 25% of the total number of shares of common stock subject to the option will vest on January 1, 2015, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.